Idogen’s cell technology successfully advanced to large-scale production
Idogen AB (Spotlight Stock Market: IDOGEN) has today announced that the company’s technology platform for tolerogenic dendritic cell generation has been successfully advanced from pilot to production-scale. Results from completed tests show that the technology platform can now generate functional cells in considerably larger volumes than previously possible. As the next step, Idogen now initiates the partnership with Radboud University Medical Center in the Netherlands, to establish cell production meeting Good Manufacturing Practice (GMP) requirements prior to upcoming clinical trials.